급성 심부전의 치료 = Acute Heart Failure and Its Management

다국어 초록 (Multilingual Abstract)

The prevalence of heart failure (HF) is rapidly increasing throughout the world, and is closely associated with serious morbidity and mortality. In particular, acute HF is one of the main causes of hospitalization and mortality, especially in elderly individuals. In Korea, the socioeconomic burden of HF is substantial. Because of this, the Korean HF society developed chronic and acute HF management guidelines in 2017, adapted process while including as much data from Korean studies as possible. The scope of the current review, which is based on the Korean HF guidelines, includes the definition, diagnosis, and treatment of acute HF with reduced or preserved ejection fractions of various etiologies.

참고문헌 (Reference)

1 Cowie MR, "Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care" 350 : 1349-1353, 1997

2 Krishnaswamy P, "Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction" 111 : 274-279, 2001

3 Costanzo M, "Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure" 49 : 675-683, 2007

4 Costanzo M, "Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD" 16 : 277-284, 2010

5 Bart B, "Ultrafiltration in decompensated heart failure with cardiorenal syndrome" 367 : 2296-2304, 2012

6 Youn YJ, "Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure: report from the Korean Heart Failure Registry" 76 : 1151-1158, 2012

7 Fuat A, "The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure" 56 : 327-333, 2006

8 윤종찬, "Temporal Trends of Hospitalized Patients with Heart Failure in Korea" 대한심장학회 47 (47): 16-24, 2017

9 Ezekowitz JA, "Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)" 157 : 219-228, 2009

10 Kelder JC, "Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis" 97 : 959-963, 2011

11 Pathak A, "Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects" 38 : 341-349, 2013

12 Cheng JM, "Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials" 30 : 2102-2108, 2009

13 Cuffe M, "Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial" 287 : 1541-1547, 2002

14 Nielsen OW, "Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability" 64 : 619-628, 2004

15 Zois NE, "Natriuretic peptides in cardiometabolic regulation and disease" 11 : 403-412, 2014

16 Gupta DK, "Natriuretic peptides and cardiometabolic health" 79 : 1647-1655, 2015

17 Tang X, "Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis" 117 : 186-194, 2015

18 Januzzi JL Jr, "Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study" 50 : 607-613, 2007

19 Cox ZL, "Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy" 20 : 611-622, 2014

20 Mebazaa A, "Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE" 11 : 304-311, 2009

21 Clemo H, "Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias" 81 : 594-598, 1998

22 Thiele H, "Intraaortic balloon support for myocardial infarction with cardiogenic shock" 367 : 1287-1296, 2012

23 Thiele H, "Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial" 382 : 1638-1645, 2013

24 Fang J, "Heart failure-related hospitalization in the U.S., 1979 to 2004" 52 : 428-434, 2008

25 Thom T, "Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee" 113 : e85-e151, 2006

26 Fermann GJ, "Galectin 3 complements BNP in risk stratification in acute heart failure" 17 : 706-713, 2012

27 Bartlett RH, "Extracorporeal life support: the University of Michigan experience" 283 : 904-908, 2000

28 Jung Hoon Lee, "Epidemiology of Heart Failure in Korea: Present and Future" 대한심장학회 46 (46): 658-664, 2016

29 Konstam M, "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial" 297 : 1319-1331, 2007

30 Felker GM, "Diuretic strategies in patients with acute decompensated heart failure" 364 : 797-805, 2011

31 Gustafsson F, "Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure" 11 (11): S15-S20, 2005

32 Mentz RJ, "Decongestion in acute heart failure" 16 : 471-482, 2014

33 Nishikimi T, "Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides" 57 : 131-140, 2011

34 O’Connor C, "Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)" 138 : 78-86, 1999

35 Kelder JC, "Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure" 17 : 729-734, 2011

36 Yamamoto K, "Clinical criteria and biochemical markers for the detection of systolic dysfunction" 6 : 194-200, 2000

37 Nohria A, "Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure" 41 : 1797-1804, 2003

38 최동주, "Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry" 대한심장학회 41 (41): 363-371, 2011

39 Peacock WF 4th, "Cardiac troponin and outcome in acute heart failure" 358 : 2117-2126, 2008

40 Chen YS, "Analysis and results of prolonged resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation" 41 : 197-203, 2003

41 Hou Z, "Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study" 16 : 521-528, 1995

42 O'Neill WW, "A prospective, randomized clinical trial of hemodynamic support with impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study" 126 : 1717-1727, 2012

43 Ponikowski P, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC" 18 : 891-975, 2016